That's a good observation, Assen: “The Board is now examining its options for the future use of NTCELL as a treatment for Parkinson’s disease” (today's news release). In my opinion, if these "options" are being studied at the board level, I wonder what some of those "options" may be? JV offers, Buy-out offers? Clearly they have been busy lately.
Also, Some Other Information Noticed In Today's News Release...i.e. the "other projects" will be updated later this quarter...
"As well as NTCELL, LCT is also advancing research collaborations with the University of Auckland to identify products that are candidates for out licensing to global pharmaceutical companies. Projects that have been initiated target obesity and migraine where the lead product candidates utilise patented novel peptide synthetic chemistry technology. LCT will provide updates on these projects later this quarter."
Ann: NTCELL Parkinsons trial 2 year data analysis shows success, page-40
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.001(20.0%) |
Mkt cap ! $10.12M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.6¢ | $3.71K | 620.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 5435376 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 627656 | 2 |
View Market Depth
| Last trade - 15.41pm 07/08/2025 (20 minute delay) ? |
| 1AI (ASX) Chart |